ClinicalTrials.gg
RecruitingNCT07351656Updated Aug 20, 2026

A Study Of Heart Disease Using AI-Enabled Electrocardiography And Focused Cardiac Ultrasound

An interventional study of Focused Cardiac Ultrasound and 6-Lead AI-ECG in Heart Disease, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
19,300
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Heart Diseases by Mayo Clinic — 3 open to participants now, 4 under way, none of them phase 3. Heart Diseases · Mayo Clinic.

Started
2026
with 1 other
No phase
5 of 22
2 open now
Registered
21st of 22
by date

Among the 22 studies in Heart Diseases by Mayo Clinic, this one is one of 2 that started in 2026, is one of 5 with no phase, and was the 21st registered.

Heart Diseases

2,135 studies on the registry are indexed under Heart Diseases; 250 are open to participants now.

Browse Heart Diseases studies →

Open to participants now

3 of the 22 studies in Heart Diseases by Mayo Clinic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 182 Heart Diseases studies recruiting now, 128 (70%) set no upper age limit and 22 (12%) stop at 75 or younger; 33 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Heart Diseases by Mayo Clinic, or all of them as a file.
02

Study summary

A study to evaluate feasibility, diagnostic yield, accuracy, and actionable thresholds of POC, immediate-feedback AI-ECG + AI FoCUS screening for cardiac disease in well described community populations.

03

Conditions studied

  • Heart Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Adolescents and young adults:

Inclusion Criteria:

  • Enrollment in a high-school, college or a resident in MN during the study period
  • Age 18-29 years
  • (and assent for minors)

Exclusion Criteria:

  • Presence of a pacemaker or defibrillator
  • Inability to obtain a quality tracing

Community dwelling adults:

Inclusion Criteria:

  • Adult patients (>30 years of age, with pre-specified subgroups 30-64 and 65+))

Exclusion Criteria:

  • Inability to provide informed consent to participate in the study

Pregnant women:

Inclusion Criteria:

  • Adult female aged 18 to 49 years
  • Pregnant at the time of enrollment
  • Receiving obstetric care at identified study site(s)
  • Willing and able to provide informed consent

Exclusion Criteria:

  • Inability to provide consent
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
19,300 participants (estimated)

Study arms

  • Experimental
    Community dwelling adults

    Diagnostic Test: Focused Cardiac Ultrasound · Diagnostic Test: 6-Lead AI-ECG · Diagnostic Test: 12-Lead AI-ECG

  • Experimental
    Pregnant women

    Diagnostic Test: Focused Cardiac Ultrasound · Diagnostic Test: 6-Lead AI-ECG · Diagnostic Test: 12-Lead AI-ECG

  • Experimental
    Adolescents and young adults

    Diagnostic Test: Focused Cardiac Ultrasound · Diagnostic Test: 6-Lead AI-ECG · Diagnostic Test: 12-Lead AI-ECG

Interventions

  • Diagnostic testFocused Cardiac Ultrasound

    Focused cardiac ultrasound will utilize sonography to evaluate specific cardiac conditions, such as ventricular function, pericardial effusion, and valvular abnormalities.

  • Diagnostic test6-Lead AI-ECG

    A 6-lead ECG uses six electrodes placed on the chest and limbs to record the heart's electrical activity from multiple perspectives.

  • Diagnostic test12-Lead AI-ECG

    A standard 12-lead ECG consists of 12 leads: 6 limb leads and 6 chest (precordial) leads. These leads record the heart's electrical activity from different angles to provide a comprehensive assessment of cardiac function.

06

What researchers measure

Primary outcomes

  1. Percentage of participants with positive AI-ECG findings confirmed by echocardiography (Adolescents and young adults)

    The percentage will be calculated as the number of participants whose AI-ECG results indicate a positive finding and are subsequently confirmed by echocardiography, divided by the total number of participants assessed, multiplied by 100.

    Time frame: Baseline

  2. Number of patients with positive AI-ECG detection for left-right sided SHD (Community Dwelling Adults)

    Number of patients with positive AI-ECG detection for left-right sided SHD, defined as any of the following: LVEF \<50%, \>moderate right ventricular systolic dysfunction, \>moderate aortic, mitral, or tricuspid valve regurgitation or stenosis, pulmonary hypertension (right ventricular systolic pressure \> 50 mmHg), or elevated left-sided filling pressure.

    Time frame: Baseline

  3. Number of times the AI-ECG provides a correct diagnosis of clinically significant cardiac disease (Pregnant women)

    Diagnostic performance of the AI-ECG will be determined by the accurate diagnosis of cardiomyopathy (left ventricular ejection fraction \[LVEF\] ≤50% or 10% or more decline in LVEF) or clinically significant structural heart disease (SHD; ≥ moderate right ventricular systolic dysfunction, ≥ moderate aortic, mitral, or tricuspid valve regurgitation or stenosis, pulmonary hypertension \[right ventricular systolic pressure \> 50 mmHg\], or myocardial disease such as hypertrophic cardiomyopathy) in pregnant patients and those up to 6 weeks postpartum compared to standard of care.

    Time frame: Baseline

Secondary outcomes

  1. Number of false positive AI-ECG Results (Adolescents and young adults)

    Number of false positive AI-ECG results will be determined by the number of positive AI-ECG results proven false from an echocardiography

    Time frame: Baseline

  2. Number of positive AI-ECG results for hypertrophic cardiomyopathy (HCM) (Adolescents and young adults)

    The number of positive AI-ECG results for HCM will be based on how many patient ECGs indicate a possible diagnosis of HCM

    Time frame: Baseline

  3. Number of positive AI-ECG results for congenital heart defect (CHD) (Adolescents and young adults)

    The number of positive AI-ECG results for CHD will be based on how many patient ECGs indicate a possible diagnosis of CHD

    Time frame: Baseline

  4. Proportion of patients by age group to receive a diagnosis (Community Dwelling Adults)

    Proportion of patients by age group (30-39, 40-49, 50-65, 65-74, and 75 years and older) to receive a diagnosis from ultrasound that is confirmed by a comprehensive diagnostic work up.

    Time frame: Baseline

  5. Proportion of total patients to receive a diagnosis based on screening with 6 lead ECG (Community Dwelling Adults)

    Proportion of total patients to receive a diagnosis based on screening with 6 lead ECG will be determined by the number of patients to have a correct diagnosis using the 6 lead ECG confirmed by echocardiogram compared to the total number of patients.

    Time frame: Baseline

  6. Proportion of total patients to receive a diagnosis based on screening with 12 lead ECG (Community Dwelling Adults)

    Proportion of total patients to receive a diagnosis based on screening with 12 lead ECG will be determined by the number of patients to have a correct diagnosis using the 12 lead ECG confirmed by echocardiogram compared to the total number of patients.

    Time frame: Baseline

  7. Proportion of total patients to receive a diagnosis based on screening with 12 lead only AI-ECG with adjunctive FoCUS (Community Dwelling Adults)

    Proportion of total patients to receive a diagnosis based on screening with 12 lead only AI-ECG with adjunctive FoCUS will be determined by the number of patients to have a correct diagnosis using the 12 lead ECG with adjunctive FoCUS confirmed by standard of care echocardiogram compared to the total number of patients.

    Time frame: Baseline

  8. Proportion of total patients to receive a diagnosis based on screening with 12 lead only AI-ECG without adjunctive FoCUS (Community Dwelling Adults)

    Proportion of total patients to receive a diagnosis based on screening with 12 lead only AI-ECG without adjunctive FoCUS will be determined by the number of patients to have a correct diagnosis using the 12 lead ECG without adjunctive FoCUS confirmed by standard of care echocardiogram compared to the total number of patients.

    Time frame: Baseline

  9. Number of non-cardiac adverse events (Pregnant Women)

    Number of non-cardiac adverse events can include hypertensive disorders of pregnancy (gestational hypertension, pre-eclampsia, eclampsia), preterm delivery, gestational diabetes, small for gestational age delivery, placental abruption, and pregnancy loss.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Feb 2028, 23 months after the start.

Of 264 non-industry interventional studies with no phase under Heart Diseases, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's planned 23 months is close to that.

Counting every sponsor, half of 337 studies reached it within 25 months; a quarter within 11 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2026
First posted
Jan 20, 2026
StartActual
Mar 9, 2026
Primary completionEst.
Feb 2028
CompletionEst.
Feb 2028
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07351656
Lead sponsor
Mayo Clinic
Responsible party
Paul A. Friedman (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Jan 20, 2026
Start date
Mar 9, 2026
Primary completion
Feb 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Aug 20, 2026

Study contacts

Amanda Priebe
Contact
Priebe.Amanda@mayo.edu
507-422-6932
Paul Friedman, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion